Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Announces-That-The-American-Journal-of-Gastroenterology-Publishes-Full-Results-from-Positive-LINZESS-linaclotide-Phase-IIIb-Trial-in-Adults-with-Irritable-Bowel-Syndrome-with-Constipation-IBS-C/default.aspx
Ironwood Pharmaceuticals Announces Leadership Updates
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Announces-Leadership-Updates/default.aspx
Ironwood Pharmaceuticals Announces Leadership Updates
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Announces-Leadership-Updates/default.aspx
Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Announces-Agreement-with-Teva-Involving-LINZESS-linaclotide-72-mcg-Dosage-Strength/default.aspx
Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Announces-Agreement-with-Teva-Involving-LINZESS-linaclotide-72-mcg-Dosage-Strength/default.aspx
More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/More-Than-a-Third-of-Surveyed-IBS-C-Patients-Reported-That-Their-Symptoms-Worsened-During-COVID-19-According-to-New-Survey-Findings-Presented-by-Ironwood-Pharmaceuticals-at-Digestive-Disease-Week-DDW/default.aspx
More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/More-Than-a-Third-of-Surveyed-IBS-C-Patients-Reported-That-Their-Symptoms-Worsened-During-COVID-19-According-to-New-Survey-Findings-Presented-by-Ironwood-Pharmaceuticals-at-Digestive-Disease-Week-DDW/default.aspx
Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-to-Present-New-Linaclotide-Data-and-Unveil-Findings-From-GI-Disease-Surveys-at-Digestive-Disease-Week-2021/default.aspx
Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-to-Present-New-Linaclotide-Data-and-Unveil-Findings-From-GI-Disease-Surveys-at-Digestive-Disease-Week-2021/default.aspx
Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program
https://investor.ironwoodpharma.com/press-releases/press-release-details/2021/Ironwood-Pharmaceuticals-Announces-New-150-Million-Share-Repurchase-Program/default.aspx